Subscribe To

Price Alert Latest News Economic Calendar News

POAI / HC Wainwright reiterates ‘Buy' rating on Predictive Oncology and $5 price target

Analysts at HC Wainwright repeated their 'Buy' rating on Predictive Oncology Inc and $5 price target, noting that the company's artificial intelligence (AI) platform has executed “important early steps” and demonstrated “promising predictive capability". Minneapolis, Minnesota-based Predictive Oncology's subsidiary Helomics announced initial results in August last year showing that its AI-driven models of genomic data can predict cancer outcomes. Read More

Demo Live Account See Partner Details

Content Topics

Ascent

Resources

Plc

Ast

Wainwright

Reiterates

buy

Rating

Predictive

Oncology

Target

Stock

POAI

Posted: Jan 25 2022, 13:44

Author Name: Proactive Investors

POAI News

By Seeking Alpha
August 10, 2023

Predictive Oncology, Inc. (POAI) Q2 2023 Earnings Call Transcript

Predictive Oncology, Inc. (NASDAQ:POAI ) Q2 2023 Earnings Conference Call August 10, 2023 5:30 PM ET Company Participants Glenn Garmont - Managing Dir

By Proactive Investors
August 10, 2023

Predictive Oncology dramatically narrows its quarterly loss in latest financial results

Predictive Oncology reported its second-quarter financial results after the bell Thursday, including a significantly narrower loss than the same quart

By Proactive Investors
July 18, 2023

Predictive Oncology moves company headquarters to Pittsburgh

Predictive Oncology Inc. (NASDAQ:POAI) announced that it has moved its corporate headquarters to its main laboratory facility in Pittsburgh, Pennsylva

By Proactive Investors
June 27, 2023

Predictive Oncology adds biopharmaceutical CFO Andrew Einhorn to business advisory board

Predictive Oncology Inc. (NASDAQ:POAI) has announced the addition of biopharmaceutical finance industry veteran Andrew Einhorn to its business advisor

By Proactive Investors
June 20, 2023

Predictive Oncology appoints Dr Bernard Harris Jr to Business Advisory Board

Predictive Oncology Inc. (NASDAQ:POAI) has announced the appointment of Dr Bernard Harris Jr to its newly-formed Business Advisory Board (BAB). The

By Proactive Investors
May 16, 2023

Predictive Oncology forges key partnerships to drive oncology drug development in 1Q

Predictive Oncology has updated investors on its use of artificial intelligence (AI) and machine learning and its extensive biorepository of tumor s

By Seeking Alpha
May 15, 2023

Predictive Oncology, Inc. (POAI) Q1 2023 Earnings Conference Call Transcript

Predictive Oncology, Inc. (NASDAQ:POAI ) Q1 2023 Earnings Conference Call May 15, 2023 5:30 PM ET Company Participants Glenn Garmont - Managing Direct

By Proactive Investors
April 4, 2023

Predictive Oncology appoints translational research leader Christoph Reinhard to scientific advisory board

Predictive Oncology Inc. (NASDAQ:POAI) announced the appointment of Dr. Christoph Reinhard to its scientific board to serve alongside other key though

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.